Inogen (NASDAQ:INGN) Rating Increased to Strong-Buy at Freedom Capital

Freedom Capital upgraded shares of Inogen (NASDAQ:INGN) to a strong-buy rating in a report released on Tuesday,Zacks.com reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Inogen Stock Performance

Shares of Inogen stock opened at $6.80 on Tuesday. Inogen has a one year low of $5.34 and a one year high of $9.13. The company has a market cap of $185.16 million, a price-to-earnings ratio of -7.91 and a beta of 1.70. The business’s 50 day moving average price is $6.08 and its 200 day moving average price is $6.90.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, February 24th. The medical technology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.10. Inogen had a negative return on equity of 11.56% and a negative net margin of 6.52%.The firm had revenue of $81.72 million for the quarter, compared to the consensus estimate of $82.00 million. On average, analysts predict that Inogen will post -1.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Inogen

A number of institutional investors have recently added to or reduced their stakes in INGN. Armistice Capital LLC increased its stake in Inogen by 46.3% during the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the medical technology company’s stock worth $8,494,000 after acquiring an additional 400,000 shares during the last quarter. Kent Lake PR LLC increased its stake in Inogen by 5.7% during the second quarter. Kent Lake PR LLC now owns 1,061,294 shares of the medical technology company’s stock worth $7,461,000 after acquiring an additional 57,700 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Inogen by 0.8% during the second quarter. Ameriprise Financial Inc. now owns 881,100 shares of the medical technology company’s stock worth $6,194,000 after acquiring an additional 6,573 shares during the last quarter. Geode Capital Management LLC increased its stake in Inogen by 7.9% during the second quarter. Geode Capital Management LLC now owns 615,279 shares of the medical technology company’s stock worth $4,326,000 after acquiring an additional 44,860 shares during the last quarter. Finally, Royce & Associates LP increased its stake in Inogen by 15.2% during the third quarter. Royce & Associates LP now owns 600,968 shares of the medical technology company’s stock worth $4,910,000 after acquiring an additional 79,238 shares during the last quarter. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.